Drugs / ABI-007
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01478685 | Nov 2011 → Nov 2015 | fallopian tube neoplasm, non-small cell lung carcinoma, ovarian neoplasm, pancreatic ductal adenocarcinoma +4 | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00731380 | Jul 2008 → Jun 2016 | head and neck cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT00407407 | Nov 2006 → Feb 2008 | fallopian tube neoplasm, ovarian neoplasm, peritoneal neoplasm | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT00095914 | Sep 2004 → May 2007 | cancer of unknown primary site | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00046423 | Apr 2000 → ? | metastatic neoplasm, neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00140140 | Aug 2005 → Feb 2008 | breast cancer | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00073723 | Dec 2003 → Jan 2007 | non-small cell lung carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 212 trials · 1 met primary | ||||||
| Phase 2 | NCT02103062 | May → Nov 2014 | colorectal neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01964534 | Dec 2013 → Feb 2017 | malignant pancreatic neoplasm | GERCOR - Multidisciplinary Oncology Cooperative Group | Unknown | Met primary |
| Phase 2 | NCT01827111 | Apr 2013 → Sep 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00661167 | Apr 2008 → May 2011 | gastric cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00456846 | Feb 2008 → Dec 2012 | breast cancer | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00483301 | May 2007 → Aug 2009 | melanoma | Mt. Sinai Medical Center, Miami | Completed | No outcome recorded |
| Phase 2 | NCT00394082 | Jun 2006 → Sep 2009 | breast cancer | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00249002 | Nov 2005 → Nov 2007 | — | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00274456 | Nov 2005 → Mar 2008 | breast cancer | Celgene Corporation | Completed | Mixed |
| Phase 2 | NCT00274443 | Mar 2005 → Jun 2007 | non-small cell lung carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00093119 | Jul 2003 → Feb 2005 | melanoma, metastatic neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00046514 | Jun 2001 → ? | breast neoplasm, metastatic neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00864253 | Apr 2009 → Jun 2012 | melanoma | Celgene Corporation | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00820768 Background | Apr 2012 → Apr 2013 | cancer | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 1 | NCT00004074 Background | Aug 1999 → Feb 2009 | PPoma, adenoid cystic carcinoma, adrenal cortex carcinoma, anal squamous cell carcinoma +45 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00503750 Comparator | Apr 2008 → Jul 2011 | breast cancer | Emory University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-007 | “Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors” NCT00095914 ↗22“A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies” NCT00820768 ↗ |
| Known as | Abraxane | “A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies” NCT00820768 ↗3“ABI-007 (Abraxane) and Carboplatin” NCT00274443 ↗ “ABI-007 (Abraxane)” NCT00503750 ↗ “ABI-007(Abraxane)” NCT00483301 ↗ |
| Route | Intravenous | “by intravenous route” NCT00046423 ↗ |